Novartis Vaccines clinical trials

Formerly part of Novartis, 2015 · source ↗

The registry lists 165 studies whose lead sponsor is Novartis Vaccines. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 24, 2024.

Studies

Recruiting first, then most recently updated. Showing 50 of 165. List all 165 → · All Novartis studies →

• Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult SubjectsCompletedNCT00630331Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012CompletedNCT01344057Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaCompletedNCT01725217Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28CompletedNCT01894919Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy SubjectsCompletedNCT01342796Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly SubjectsCompletedNCT01161264Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young AdultsCompletedNCT01272180Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS VaccineCompletedNCT01053767Phase 1

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of AgeCompletedNCT00971906Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)CompletedNCT00310804Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and ElderlyCompletedNCT00306527Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or OlderCompletedNCT01222403Phase 4

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 YearsCompletedNCT01928472Phase 1

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult SubjectsCompletedNCT02256488Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination SchedulesCompletedNCT00661713Phase 2/3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly SubjectsCompletedNCT01766921Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in ChildrenCompletedNCT01776554Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare SystemsCompletedNCT01734434

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of AgeCompletedNCT00329849Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of LifeCompletedNCT01214837Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)CompletedNCT00310856Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same VaccineCompletedNCT01027351Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy AdolescentsCompletedNCT02140762Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy AdolescentsCompletedNCT00262041Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate VaccineCompletedNCT01345721Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10CompletedNCT01148524Phase 2/3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00657709Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate VaccineCompletedNCT01148017Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12CompletedNCT00944034Phase 2/3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Persistence of Antibody Response to N. Meningitidis Group C in ChildrenCompletedNCT00316654Phase 4

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate VaccineCompletedNCT00856297Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate VaccineCompletedNCT01453348Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.CompletedNCT01911221Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 MonthsCompletedNCT00996307Phase 2/3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of AgeCompletedNCT01470287Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy WomenCompletedNCT01150123Phase 1

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related ComplicationsCompletedNCT01998477Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy AdultsCompletedNCT00264576Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA VaccineCompletedNCT01098786

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit VaccineCompletedNCT01037855

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative AdultsCompletedNCT00736476Phase 1

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and AboveCompletedNCT01880697Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.CompletedNCT02255279Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy ChildrenCompletedNCT01125527Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean ChildrenCompletedNCT01404962Phase 4

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly SubjectsCompletedNCT00518726Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 StudyCompletedNCT00644540Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly SubjectsCompletedNCT01069367Phase 4

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination SchedulesCompletedNCT00848029Phase 3

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis

• Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.CompletedNCT00522067Phase 2

  Sponsor listed in the registry: Novartis Vaccines · First submitted before Novartis Vaccines left Novartis